| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Atrial Fibrillation | 57 | 2025 | 854 | 10.200 |
Why?
|
| Catheter Ablation | 33 | 2025 | 155 | 7.030 |
Why?
|
| Defibrillators, Implantable | 34 | 2023 | 267 | 5.620 |
Why?
|
| Simian Immunodeficiency Virus | 26 | 2023 | 81 | 4.860 |
Why?
|
| Health Care Costs | 20 | 2021 | 215 | 4.830 |
Why?
|
| Aortic Valve Stenosis | 22 | 2019 | 190 | 4.610 |
Why?
|
| Simian Acquired Immunodeficiency Syndrome | 21 | 2023 | 59 | 4.560 |
Why?
|
| Heart Valve Prosthesis Implantation | 20 | 2021 | 176 | 4.230 |
Why?
|
| Anti-Arrhythmia Agents | 16 | 2024 | 103 | 3.400 |
Why?
|
| Cardiac Catheterization | 19 | 2024 | 292 | 3.340 |
Why?
|
| Stroke | 17 | 2024 | 1196 | 3.260 |
Why?
|
| Cost-Benefit Analysis | 30 | 2023 | 318 | 2.810 |
Why?
|
| Medicare | 22 | 2025 | 611 | 2.740 |
Why?
|
| Intelligence | 9 | 2018 | 52 | 2.720 |
Why?
|
| Quality of Life | 32 | 2024 | 1257 | 2.540 |
Why?
|
| Humans | 224 | 2025 | 64279 | 2.340 |
Why?
|
| Arrhythmias, Cardiac | 11 | 2023 | 158 | 2.270 |
Why?
|
| Hospital Costs | 14 | 2021 | 126 | 2.190 |
Why?
|
| Male | 148 | 2025 | 30323 | 2.120 |
Why?
|
| Female | 154 | 2025 | 33382 | 2.050 |
Why?
|
| Health Resources | 9 | 2020 | 94 | 2.020 |
Why?
|
| Quality-Adjusted Life Years | 13 | 2023 | 67 | 1.970 |
Why?
|
| Health Status | 12 | 2018 | 447 | 1.910 |
Why?
|
| Registries | 27 | 2023 | 885 | 1.860 |
Why?
|
| Treatment Outcome | 64 | 2024 | 5697 | 1.770 |
Why?
|
| Intracranial Aneurysm | 6 | 2020 | 374 | 1.770 |
Why?
|
| Aged | 92 | 2025 | 14664 | 1.730 |
Why?
|
| Electric Countershock | 10 | 2020 | 103 | 1.710 |
Why?
|
| Postoperative Complications | 14 | 2024 | 1301 | 1.660 |
Why?
|
| Transcatheter Aortic Valve Replacement | 10 | 2019 | 112 | 1.650 |
Why?
|
| SAIDS Vaccines | 9 | 2022 | 22 | 1.560 |
Why?
|
| Health Expenditures | 5 | 2023 | 122 | 1.530 |
Why?
|
| United States | 63 | 2025 | 7923 | 1.510 |
Why?
|
| Hospitalization | 19 | 2024 | 1368 | 1.480 |
Why?
|
| Pacemaker, Artificial | 4 | 2020 | 49 | 1.420 |
Why?
|
| Cardiac Resynchronization Therapy | 4 | 2021 | 20 | 1.420 |
Why?
|
| Aortic Valve | 9 | 2019 | 190 | 1.380 |
Why?
|
| Aged, 80 and over | 53 | 2024 | 5528 | 1.370 |
Why?
|
| Anticoagulants | 12 | 2024 | 511 | 1.350 |
Why?
|
| tau Proteins | 9 | 2008 | 204 | 1.340 |
Why?
|
| Intracranial Arteriovenous Malformations | 5 | 2021 | 80 | 1.320 |
Why?
|
| Psychometrics | 7 | 2024 | 385 | 1.240 |
Why?
|
| Hemorrhage | 5 | 2024 | 275 | 1.230 |
Why?
|
| Middle Aged | 77 | 2024 | 17923 | 1.230 |
Why?
|
| Retrospective Studies | 45 | 2025 | 6742 | 1.230 |
Why?
|
| Time Factors | 33 | 2024 | 3726 | 1.230 |
Why?
|
| Tachycardia, Ventricular | 7 | 2024 | 131 | 1.170 |
Why?
|
| Subarachnoid Hemorrhage | 5 | 2015 | 109 | 1.160 |
Why?
|
| Carotid Stenosis | 3 | 2014 | 98 | 1.130 |
Why?
|
| Myocardial Infarction | 7 | 2019 | 915 | 1.130 |
Why?
|
| Follow-Up Studies | 29 | 2024 | 2482 | 1.130 |
Why?
|
| Coronary Artery Bypass | 7 | 2021 | 297 | 1.120 |
Why?
|
| Intelligence Tests | 6 | 2017 | 26 | 1.120 |
Why?
|
| Risk Assessment | 19 | 2024 | 2049 | 1.100 |
Why?
|
| Warfarin | 4 | 2017 | 122 | 1.090 |
Why?
|
| Renal Insufficiency, Chronic | 3 | 2021 | 147 | 1.070 |
Why?
|
| Cerebral Revascularization | 4 | 2018 | 30 | 1.070 |
Why?
|
| Embolization, Therapeutic | 5 | 2020 | 328 | 1.060 |
Why?
|
| Macaca mulatta | 22 | 2023 | 256 | 1.060 |
Why?
|
| Macaca fascicularis | 7 | 2023 | 48 | 1.060 |
Why?
|
| Heart Failure | 9 | 2017 | 926 | 1.060 |
Why?
|
| Nitrates | 5 | 2008 | 22 | 1.050 |
Why?
|
| Percutaneous Coronary Intervention | 7 | 2021 | 222 | 1.050 |
Why?
|
| Pulmonary Veins | 6 | 2025 | 36 | 1.040 |
Why?
|
| CD8-Positive T-Lymphocytes | 12 | 2023 | 679 | 1.030 |
Why?
|
| Atrial Appendage | 2 | 2024 | 38 | 1.020 |
Why?
|
| Endovascular Procedures | 5 | 2018 | 607 | 1.000 |
Why?
|
| Insurance Benefits | 2 | 2024 | 7 | 0.990 |
Why?
|
| Memory, Short-Term | 3 | 2022 | 60 | 0.940 |
Why?
|
| Risk Factors | 34 | 2024 | 5342 | 0.940 |
Why?
|
| Pyridones | 2 | 2017 | 42 | 0.940 |
Why?
|
| Cerebral Angiography | 7 | 2020 | 295 | 0.930 |
Why?
|
| Mitral Valve Insufficiency | 4 | 2021 | 95 | 0.910 |
Why?
|
| Virus Replication | 9 | 2023 | 323 | 0.910 |
Why?
|
| Pyrazoles | 2 | 2017 | 87 | 0.910 |
Why?
|
| Death, Sudden, Cardiac | 9 | 2023 | 362 | 0.890 |
Why?
|
| Atherosclerosis | 4 | 2019 | 156 | 0.880 |
Why?
|
| Brain Neoplasms | 3 | 2018 | 313 | 0.880 |
Why?
|
| Histocompatibility Antigens Class I | 8 | 2017 | 145 | 0.880 |
Why?
|
| Cognition | 5 | 2018 | 491 | 0.880 |
Why?
|
| Severity of Illness Index | 16 | 2019 | 1561 | 0.870 |
Why?
|
| Syncope | 2 | 2023 | 42 | 0.860 |
Why?
|
| Wechsler Scales | 6 | 2018 | 16 | 0.860 |
Why?
|
| Electrocardiography, Ambulatory | 2 | 2023 | 46 | 0.850 |
Why?
|
| Factor Analysis, Statistical | 7 | 2024 | 99 | 0.840 |
Why?
|
| Graft vs Host Disease | 2 | 2022 | 116 | 0.840 |
Why?
|
| Ergot Alkaloids | 1 | 2024 | 1 | 0.840 |
Why?
|
| Animal Feed | 1 | 2024 | 16 | 0.840 |
Why?
|
| Adolescent | 24 | 2020 | 6305 | 0.830 |
Why?
|
| Achievement | 2 | 2015 | 29 | 0.830 |
Why?
|
| Monitoring, Physiologic | 3 | 2021 | 163 | 0.830 |
Why?
|
| Methacrylates | 1 | 2023 | 40 | 0.820 |
Why?
|
| Cryosurgery | 4 | 2018 | 26 | 0.820 |
Why?
|
| Ambulatory Care | 6 | 2017 | 317 | 0.800 |
Why?
|
| Stents | 7 | 2020 | 493 | 0.790 |
Why?
|
| Reading | 2 | 2015 | 93 | 0.770 |
Why?
|
| Cholesterol, LDL | 3 | 2019 | 104 | 0.770 |
Why?
|
| Angioplasty, Balloon, Coronary | 6 | 2012 | 167 | 0.760 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 2 | 2022 | 356 | 0.740 |
Why?
|
| Aneurysm, Ruptured | 2 | 2015 | 79 | 0.730 |
Why?
|
| Neuropsychological Tests | 5 | 2024 | 397 | 0.730 |
Why?
|
| Intermittent Claudication | 4 | 2015 | 52 | 0.710 |
Why?
|
| Device Removal | 2 | 2020 | 65 | 0.710 |
Why?
|
| Antibodies, Monoclonal | 6 | 2023 | 870 | 0.710 |
Why?
|
| Cohort Studies | 21 | 2023 | 2605 | 0.700 |
Why?
|
| Neurofibrillary Tangles | 6 | 2008 | 11 | 0.690 |
Why?
|
| HIV Infections | 3 | 2023 | 976 | 0.690 |
Why?
|
| Recurrence | 12 | 2021 | 652 | 0.690 |
Why?
|
| Prospective Studies | 22 | 2023 | 3318 | 0.680 |
Why?
|
| Brain Ischemia | 3 | 2014 | 421 | 0.680 |
Why?
|
| Cardiac Resynchronization Therapy Devices | 2 | 2017 | 7 | 0.670 |
Why?
|
| Heart Valve Prosthesis | 5 | 2016 | 114 | 0.670 |
Why?
|
| Minor Histocompatibility Antigens | 1 | 2020 | 35 | 0.660 |
Why?
|
| Alzheimer Disease | 8 | 2016 | 749 | 0.660 |
Why?
|
| Insurance, Health, Reimbursement | 4 | 2019 | 42 | 0.660 |
Why?
|
| Craniocerebral Trauma | 2 | 2018 | 55 | 0.650 |
Why?
|
| Carotid Artery Injuries | 2 | 2018 | 12 | 0.650 |
Why?
|
| Adult | 28 | 2023 | 17133 | 0.650 |
Why?
|
| Mitral Valve | 5 | 2020 | 127 | 0.640 |
Why?
|
| Carotid Artery, Internal | 2 | 2018 | 68 | 0.640 |
Why?
|
| Drug-Eluting Stents | 4 | 2021 | 66 | 0.640 |
Why?
|
| Thrombectomy | 1 | 2022 | 242 | 0.630 |
Why?
|
| Cytidine Deaminase | 1 | 2020 | 86 | 0.630 |
Why?
|
| Neurosurgical Procedures | 4 | 2018 | 101 | 0.630 |
Why?
|
| Drug Costs | 5 | 2021 | 57 | 0.620 |
Why?
|
| Atrial Flutter | 4 | 2014 | 27 | 0.610 |
Why?
|
| Child | 15 | 2024 | 4583 | 0.610 |
Why?
|
| Cardiac Catheters | 2 | 2018 | 12 | 0.610 |
Why?
|
| Acute Coronary Syndrome | 2 | 2021 | 253 | 0.610 |
Why?
|
| Hypolipidemic Agents | 1 | 2019 | 25 | 0.600 |
Why?
|
| Animals | 37 | 2024 | 20962 | 0.600 |
Why?
|
| Models, Statistical | 5 | 2014 | 309 | 0.600 |
Why?
|
| Models, Psychological | 4 | 2017 | 99 | 0.600 |
Why?
|
| Surveys and Questionnaires | 15 | 2017 | 2738 | 0.600 |
Why?
|
| Angina, Unstable | 1 | 2019 | 58 | 0.600 |
Why?
|
| Tyrosine | 5 | 2008 | 94 | 0.600 |
Why?
|
| Arteries | 2 | 2019 | 80 | 0.590 |
Why?
|
| Exercise Tolerance | 2 | 2017 | 79 | 0.580 |
Why?
|
| Peptide Fragments | 3 | 2016 | 417 | 0.570 |
Why?
|
| Craniopharyngioma | 1 | 2018 | 2 | 0.570 |
Why?
|
| Pituitary Neoplasms | 1 | 2018 | 21 | 0.570 |
Why?
|
| Cardiac Surgical Procedures | 3 | 2018 | 270 | 0.560 |
Why?
|
| Outpatients | 2 | 2021 | 140 | 0.560 |
Why?
|
| Peripheral Arterial Disease | 4 | 2015 | 160 | 0.560 |
Why?
|
| Laser Therapy | 1 | 2018 | 42 | 0.560 |
Why?
|
| Gaucher Disease | 1 | 2018 | 2 | 0.560 |
Why?
|
| Epitopes, T-Lymphocyte | 6 | 2020 | 184 | 0.550 |
Why?
|
| Cerebrovascular Disorders | 3 | 2018 | 81 | 0.550 |
Why?
|
| Databases, Factual | 9 | 2019 | 856 | 0.540 |
Why?
|
| Survival Analysis | 4 | 2015 | 587 | 0.540 |
Why?
|
| Factor Xa Inhibitors | 1 | 2017 | 37 | 0.540 |
Why?
|
| Equipment Failure | 2 | 2017 | 68 | 0.530 |
Why?
|
| Peptide Library | 1 | 2017 | 37 | 0.530 |
Why?
|
| Iliac Artery | 2 | 2014 | 43 | 0.530 |
Why?
|
| Exercise Therapy | 2 | 2015 | 103 | 0.520 |
Why?
|
| Brain | 7 | 2021 | 1581 | 0.520 |
Why?
|
| Arteriovenous Fistula | 1 | 2017 | 40 | 0.510 |
Why?
|
| Intraoperative Neurophysiological Monitoring | 1 | 2016 | 6 | 0.510 |
Why?
|
| Head Injuries, Penetrating | 1 | 2016 | 5 | 0.510 |
Why?
|
| Amiodarone | 2 | 2014 | 22 | 0.510 |
Why?
|
| Thromboembolism | 2 | 2017 | 73 | 0.500 |
Why?
|
| Young Adult | 16 | 2020 | 4781 | 0.500 |
Why?
|
| Cerebral Ventricles | 1 | 2016 | 29 | 0.500 |
Why?
|
| Detergents | 1 | 2016 | 34 | 0.490 |
Why?
|
| Proton Therapy | 1 | 2016 | 8 | 0.490 |
Why?
|
| Ventriculoperitoneal Shunt | 1 | 2016 | 31 | 0.490 |
Why?
|
| Moyamoya Disease | 1 | 2016 | 12 | 0.490 |
Why?
|
| Physicians | 2 | 2020 | 483 | 0.490 |
Why?
|
| Heparan Sulfate Proteoglycans | 1 | 2016 | 6 | 0.480 |
Why?
|
| Mental Processes | 2 | 2013 | 18 | 0.480 |
Why?
|
| Remote Consultation | 1 | 2016 | 17 | 0.480 |
Why?
|
| Thiophenes | 2 | 2013 | 30 | 0.480 |
Why?
|
| Writing | 2 | 2017 | 44 | 0.480 |
Why?
|
| Foreign Bodies | 1 | 2016 | 55 | 0.480 |
Why?
|
| Primary Prevention | 2 | 2014 | 136 | 0.480 |
Why?
|
| Heart Valve Diseases | 4 | 2020 | 95 | 0.480 |
Why?
|
| Muscle, Smooth, Vascular | 1 | 2016 | 48 | 0.470 |
Why?
|
| Peroxynitrous Acid | 2 | 2006 | 5 | 0.470 |
Why?
|
| Basal Ganglia | 1 | 2015 | 34 | 0.470 |
Why?
|
| Radiation Injuries | 1 | 2016 | 66 | 0.470 |
Why?
|
| Suicide, Attempted | 1 | 2016 | 107 | 0.470 |
Why?
|
| Mathematics | 1 | 2015 | 34 | 0.460 |
Why?
|
| Clinical Trials as Topic | 3 | 2023 | 460 | 0.460 |
Why?
|
| Meningeal Neoplasms | 1 | 2015 | 60 | 0.450 |
Why?
|
| Meningioma | 1 | 2015 | 61 | 0.450 |
Why?
|
| Microsurgery | 1 | 2015 | 52 | 0.450 |
Why?
|
| Age Factors | 8 | 2017 | 1570 | 0.450 |
Why?
|
| Vasoconstrictor Agents | 1 | 2015 | 70 | 0.450 |
Why?
|
| Proportional Hazards Models | 5 | 2019 | 735 | 0.450 |
Why?
|
| Hemangioblastoma | 1 | 2014 | 2 | 0.440 |
Why?
|
| von Hippel-Lindau Disease | 1 | 2014 | 4 | 0.440 |
Why?
|
| Ezetimibe | 3 | 2019 | 6 | 0.440 |
Why?
|
| Cerebellar Neoplasms | 1 | 2014 | 10 | 0.440 |
Why?
|
| Reactive Oxygen Species | 1 | 2016 | 237 | 0.440 |
Why?
|
| Incidence | 6 | 2024 | 1385 | 0.440 |
Why?
|
| Digoxin | 1 | 2014 | 22 | 0.440 |
Why?
|
| Aortic Diseases | 1 | 2014 | 65 | 0.420 |
Why?
|
| Oxidative Stress | 1 | 2016 | 304 | 0.420 |
Why?
|
| Air Travel | 1 | 2013 | 5 | 0.420 |
Why?
|
| Amyloid beta-Peptides | 1 | 2016 | 312 | 0.410 |
Why?
|
| Cardiovascular Agents | 1 | 2014 | 104 | 0.410 |
Why?
|
| Sick Leave | 2 | 2011 | 23 | 0.410 |
Why?
|
| Practice Patterns, Physicians' | 6 | 2021 | 708 | 0.400 |
Why?
|
| Activities of Daily Living | 1 | 2015 | 293 | 0.400 |
Why?
|
| Paralysis | 2 | 2012 | 17 | 0.390 |
Why?
|
| Diagnostic and Statistical Manual of Mental Disorders | 1 | 2013 | 120 | 0.390 |
Why?
|
| Length of Stay | 7 | 2020 | 819 | 0.390 |
Why?
|
| Exercise | 3 | 2017 | 954 | 0.390 |
Why?
|
| Sirolimus | 3 | 2020 | 94 | 0.390 |
Why?
|
| Receptors, Antigen, T-Cell | 3 | 2022 | 291 | 0.390 |
Why?
|
| Cost Savings | 6 | 2019 | 55 | 0.390 |
Why?
|
| Magnetic Resonance Imaging | 7 | 2020 | 2218 | 0.390 |
Why?
|
| Comorbidity | 9 | 2024 | 1119 | 0.380 |
Why?
|
| Ischemic Attack, Transient | 1 | 2013 | 97 | 0.380 |
Why?
|
| Blood Coagulation | 1 | 2013 | 39 | 0.380 |
Why?
|
| Aptitude | 3 | 2018 | 10 | 0.380 |
Why?
|
| Health Status Indicators | 3 | 2015 | 95 | 0.380 |
Why?
|
| Morpholines | 1 | 2013 | 90 | 0.380 |
Why?
|
| Sex Factors | 6 | 2017 | 980 | 0.380 |
Why?
|
| Models, Economic | 6 | 2021 | 44 | 0.380 |
Why?
|
| Central Nervous System | 1 | 2014 | 197 | 0.380 |
Why?
|
| Privacy | 1 | 2012 | 13 | 0.380 |
Why?
|
| Motor Activity | 1 | 2015 | 346 | 0.370 |
Why?
|
| Reproducibility of Results | 11 | 2024 | 1683 | 0.370 |
Why?
|
| Knowledge | 1 | 2012 | 31 | 0.370 |
Why?
|
| Computer Security | 1 | 2012 | 16 | 0.370 |
Why?
|
| Health Services | 1 | 2013 | 82 | 0.370 |
Why?
|
| Oculomotor Nerve | 1 | 2012 | 2 | 0.370 |
Why?
|
| Pupil | 1 | 2012 | 9 | 0.370 |
Why?
|
| Oculomotor Nerve Diseases | 1 | 2012 | 5 | 0.370 |
Why?
|
| Hospitals, Special | 1 | 2012 | 9 | 0.370 |
Why?
|
| Cardiac Pacing, Artificial | 3 | 2010 | 36 | 0.370 |
Why?
|
| Viral Load | 8 | 2023 | 233 | 0.370 |
Why?
|
| United States Food and Drug Administration | 1 | 2012 | 91 | 0.360 |
Why?
|
| Multivariate Analysis | 9 | 2015 | 930 | 0.360 |
Why?
|
| Macaca | 3 | 2019 | 32 | 0.360 |
Why?
|
| Certification | 1 | 2012 | 57 | 0.360 |
Why?
|
| Immunodominant Epitopes | 5 | 2011 | 57 | 0.360 |
Why?
|
| Employer Health Costs | 1 | 2011 | 1 | 0.350 |
Why?
|
| Comprehension | 1 | 2012 | 139 | 0.340 |
Why?
|
| Pancreatic Neoplasms | 1 | 2014 | 350 | 0.340 |
Why?
|
| Rhizotomy | 1 | 2011 | 1 | 0.340 |
Why?
|
| Practice Guidelines as Topic | 4 | 2014 | 726 | 0.340 |
Why?
|
| Spinal Nerve Roots | 1 | 2011 | 18 | 0.340 |
Why?
|
| Cerebral Palsy | 1 | 2011 | 19 | 0.340 |
Why?
|
| Child, Preschool | 7 | 2018 | 2019 | 0.340 |
Why?
|
| Rectum | 1 | 2011 | 93 | 0.330 |
Why?
|
| Polymorphism, Genetic | 1 | 2011 | 191 | 0.330 |
Why?
|
| Intellectual Disability | 1 | 2013 | 172 | 0.330 |
Why?
|
| Coitus | 1 | 2010 | 15 | 0.330 |
Why?
|
| Child Development | 2 | 2024 | 85 | 0.320 |
Why?
|
| Flow Cytometry | 2 | 2016 | 668 | 0.320 |
Why?
|
| Quality Assurance, Health Care | 1 | 2012 | 254 | 0.310 |
Why?
|
| Tachycardia, Ectopic Atrial | 1 | 2009 | 2 | 0.300 |
Why?
|
| Induced Pluripotent Stem Cells | 2 | 2022 | 154 | 0.300 |
Why?
|
| Electrocardiography | 4 | 2024 | 554 | 0.300 |
Why?
|
| Diagnostic Imaging | 1 | 2012 | 266 | 0.300 |
Why?
|
| Meningocele | 1 | 2008 | 4 | 0.290 |
Why?
|
| Monte Carlo Method | 3 | 2019 | 90 | 0.290 |
Why?
|
| Craniosynostoses | 1 | 2008 | 11 | 0.290 |
Why?
|
| Heart Rate | 4 | 2019 | 328 | 0.290 |
Why?
|
| Viremia | 3 | 2016 | 44 | 0.290 |
Why?
|
| Ossification, Heterotopic | 1 | 2008 | 13 | 0.290 |
Why?
|
| Propensity Score | 4 | 2024 | 167 | 0.280 |
Why?
|
| Randomized Controlled Trials as Topic | 7 | 2016 | 788 | 0.280 |
Why?
|
| Recovery of Function | 5 | 2017 | 286 | 0.280 |
Why?
|
| Comparative Effectiveness Research | 3 | 2019 | 46 | 0.280 |
Why?
|
| Heart Conduction System | 3 | 2017 | 53 | 0.270 |
Why?
|
| Gene Products, gag | 5 | 2012 | 67 | 0.270 |
Why?
|
| Data Interpretation, Statistical | 1 | 2008 | 194 | 0.270 |
Why?
|
| Occupational Diseases | 1 | 2010 | 267 | 0.270 |
Why?
|
| Protein Processing, Post-Translational | 6 | 2008 | 268 | 0.270 |
Why?
|
| Clinical Decision-Making | 3 | 2019 | 163 | 0.270 |
Why?
|
| Coronary Restenosis | 1 | 2007 | 20 | 0.270 |
Why?
|
| Echocardiography | 3 | 2020 | 509 | 0.270 |
Why?
|
| Medical Records | 1 | 2008 | 138 | 0.270 |
Why?
|
| Brachytherapy | 1 | 2007 | 39 | 0.260 |
Why?
|
| Tyrosine 3-Monooxygenase | 1 | 2007 | 35 | 0.260 |
Why?
|
| Femoral Artery | 2 | 2011 | 99 | 0.260 |
Why?
|
| alpha-Synuclein | 1 | 2007 | 36 | 0.260 |
Why?
|
| Hemostatic Techniques | 1 | 2007 | 11 | 0.260 |
Why?
|
| Vagina | 3 | 2009 | 87 | 0.260 |
Why?
|
| Remote Sensing Technology | 2 | 2017 | 7 | 0.260 |
Why?
|
| Risk | 4 | 2020 | 379 | 0.260 |
Why?
|
| Vascular Patency | 2 | 2019 | 134 | 0.260 |
Why?
|
| Markov Chains | 4 | 2019 | 37 | 0.250 |
Why?
|
| Ventricular Fibrillation | 2 | 2023 | 107 | 0.250 |
Why?
|
| Diagnosis, Differential | 3 | 2015 | 984 | 0.250 |
Why?
|
| Patient Acceptance of Health Care | 2 | 2023 | 489 | 0.250 |
Why?
|
| Boston | 4 | 2017 | 255 | 0.240 |
Why?
|
| Logistic Models | 7 | 2020 | 1270 | 0.240 |
Why?
|
| Antibiotic Prophylaxis | 2 | 2017 | 55 | 0.240 |
Why?
|
| Prosthesis Design | 5 | 2020 | 224 | 0.240 |
Why?
|
| Regression Analysis | 3 | 2014 | 498 | 0.240 |
Why?
|
| Disease Progression | 4 | 2023 | 1176 | 0.240 |
Why?
|
| Superoxide Dismutase | 1 | 2007 | 226 | 0.240 |
Why?
|
| Proteins | 1 | 2011 | 760 | 0.230 |
Why?
|
| Parkinson Disease | 1 | 2007 | 134 | 0.230 |
Why?
|
| Muscle, Skeletal | 1 | 2011 | 747 | 0.230 |
Why?
|
| Survival Rate | 8 | 2024 | 859 | 0.230 |
Why?
|
| Immunity, Innate | 1 | 2011 | 803 | 0.230 |
Why?
|
| T-Lymphocytes, Cytotoxic | 6 | 2009 | 182 | 0.230 |
Why?
|
| Cardiomyopathy, Hypertrophic | 2 | 2024 | 774 | 0.220 |
Why?
|
| Patient Admission | 2 | 2017 | 198 | 0.220 |
Why?
|
| Current Procedural Terminology | 1 | 2025 | 17 | 0.220 |
Why?
|
| Microtubules | 1 | 2006 | 210 | 0.220 |
Why?
|
| Platelet Aggregation Inhibitors | 4 | 2020 | 233 | 0.220 |
Why?
|
| Major Histocompatibility Complex | 2 | 2019 | 88 | 0.220 |
Why?
|
| Administration, Oral | 2 | 2023 | 374 | 0.220 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 2005 | 248 | 0.220 |
Why?
|
| Fee-for-Service Plans | 1 | 2024 | 68 | 0.210 |
Why?
|
| Heart Septal Defects, Ventricular | 1 | 2024 | 7 | 0.210 |
Why?
|
| Silage | 1 | 2024 | 1 | 0.210 |
Why?
|
| Seizures | 4 | 2021 | 143 | 0.210 |
Why?
|
| Edible Grain | 1 | 2024 | 27 | 0.210 |
Why?
|
| Longitudinal Studies | 4 | 2017 | 1272 | 0.210 |
Why?
|
| DNA, Complementary | 1 | 2023 | 165 | 0.200 |
Why?
|
| Office Visits | 2 | 2016 | 48 | 0.200 |
Why?
|
| Patient Readmission | 4 | 2021 | 432 | 0.200 |
Why?
|
| Bacterial Infections | 2 | 2015 | 153 | 0.200 |
Why?
|
| RNA, Viral | 4 | 2021 | 275 | 0.200 |
Why?
|
| Cattle | 1 | 2024 | 316 | 0.200 |
Why?
|
| Sotalol | 1 | 2023 | 9 | 0.200 |
Why?
|
| Vascular Diseases | 1 | 2024 | 82 | 0.190 |
Why?
|
| Dizziness | 1 | 2023 | 18 | 0.190 |
Why?
|
| Gene Products, nef | 3 | 2012 | 13 | 0.190 |
Why?
|
| Direct Service Costs | 1 | 2002 | 3 | 0.190 |
Why?
|
| Coronary Thrombosis | 1 | 2002 | 21 | 0.190 |
Why?
|
| Hirudins | 2 | 2015 | 12 | 0.190 |
Why?
|
| Natural Language Processing | 1 | 2023 | 47 | 0.190 |
Why?
|
| Coronary Artery Disease | 2 | 2019 | 320 | 0.180 |
Why?
|
| HIV | 1 | 2022 | 70 | 0.180 |
Why?
|
| Bone Marrow Transplantation | 1 | 2022 | 140 | 0.180 |
Why?
|
| Dyspnea | 1 | 2023 | 124 | 0.180 |
Why?
|
| Kaplan-Meier Estimate | 4 | 2017 | 423 | 0.180 |
Why?
|
| Prosthesis Failure | 2 | 2020 | 79 | 0.180 |
Why?
|
| Amyotrophic Lateral Sclerosis | 1 | 2007 | 508 | 0.180 |
Why?
|
| Electronic Health Records | 2 | 2023 | 368 | 0.180 |
Why?
|
| Coronary Disease | 1 | 2003 | 246 | 0.180 |
Why?
|
| Immunity, Cellular | 4 | 2012 | 178 | 0.180 |
Why?
|
| Hospital Mortality | 6 | 2021 | 870 | 0.180 |
Why?
|
| Action Potentials | 2 | 2019 | 111 | 0.180 |
Why?
|
| Myocardial Revascularization | 2 | 2012 | 76 | 0.180 |
Why?
|
| Algorithms | 3 | 2019 | 1029 | 0.180 |
Why?
|
| Prescriptions | 1 | 2021 | 33 | 0.170 |
Why?
|
| Dietary Supplements | 1 | 2024 | 239 | 0.170 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2022 | 137 | 0.170 |
Why?
|
| Equipment Design | 3 | 2018 | 362 | 0.170 |
Why?
|
| Prognosis | 5 | 2014 | 1769 | 0.170 |
Why?
|
| Chi-Square Distribution | 3 | 2017 | 412 | 0.170 |
Why?
|
| Glomus Jugulare Tumor | 1 | 2020 | 3 | 0.170 |
Why?
|
| Radiologists | 1 | 2022 | 93 | 0.170 |
Why?
|
| Anticholesteremic Agents | 2 | 2019 | 35 | 0.170 |
Why?
|
| Cranial Nerve Neoplasms | 1 | 2020 | 3 | 0.170 |
Why?
|
| Immunization | 3 | 2017 | 135 | 0.170 |
Why?
|
| Exercise Test | 2 | 2013 | 254 | 0.170 |
Why?
|
| Fractures, Stress | 1 | 2020 | 12 | 0.170 |
Why?
|
| Physical Endurance | 1 | 2020 | 48 | 0.160 |
Why?
|
| Patient Care Planning | 2 | 2017 | 83 | 0.160 |
Why?
|
| Secondary Prevention | 1 | 2021 | 164 | 0.160 |
Why?
|
| Mitral Valve Annuloplasty | 1 | 2020 | 19 | 0.160 |
Why?
|
| Diet | 1 | 2024 | 533 | 0.160 |
Why?
|
| Basilar Artery | 1 | 2020 | 32 | 0.160 |
Why?
|
| Hospitals, Low-Volume | 1 | 2020 | 20 | 0.160 |
Why?
|
| Body Composition | 1 | 2020 | 153 | 0.160 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2019 | 248 | 0.160 |
Why?
|
| Bone Marrow Cells | 1 | 2020 | 237 | 0.160 |
Why?
|
| Bone Density | 1 | 2020 | 137 | 0.160 |
Why?
|
| Hospitals, High-Volume | 1 | 2020 | 33 | 0.160 |
Why?
|
| Amino Acid Sequence | 7 | 2011 | 1597 | 0.160 |
Why?
|
| Running | 1 | 2020 | 84 | 0.150 |
Why?
|
| Disease Management | 2 | 2019 | 237 | 0.150 |
Why?
|
| Quality Improvement | 2 | 2021 | 455 | 0.150 |
Why?
|
| Plasmapheresis | 1 | 2019 | 17 | 0.150 |
Why?
|
| Electrophysiologic Techniques, Cardiac | 3 | 2008 | 24 | 0.150 |
Why?
|
| Antiphospholipid Syndrome | 1 | 2019 | 16 | 0.150 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2019 | 215 | 0.150 |
Why?
|
| Drug Tolerance | 1 | 2019 | 33 | 0.150 |
Why?
|
| Patient Care Bundles | 1 | 2018 | 11 | 0.150 |
Why?
|
| Hominidae | 1 | 2018 | 7 | 0.150 |
Why?
|
| Phrenic Nerve | 1 | 2018 | 4 | 0.150 |
Why?
|
| Lower Extremity | 1 | 2020 | 159 | 0.150 |
Why?
|
| Lymph Nodes | 5 | 2011 | 229 | 0.140 |
Why?
|
| Ventricular Dysfunction, Left | 2 | 2014 | 165 | 0.140 |
Why?
|
| Reoperation | 1 | 2020 | 292 | 0.140 |
Why?
|
| Canada | 2 | 2010 | 151 | 0.140 |
Why?
|
| Elective Surgical Procedures | 1 | 2019 | 119 | 0.140 |
Why?
|
| Peripheral Nerve Injuries | 1 | 2018 | 14 | 0.140 |
Why?
|
| Dilatation | 1 | 2018 | 31 | 0.140 |
Why?
|
| Cause of Death | 1 | 2019 | 222 | 0.140 |
Why?
|
| Rivaroxaban | 2 | 2021 | 19 | 0.140 |
Why?
|
| Interferon-gamma | 3 | 2012 | 576 | 0.140 |
Why?
|
| Health Services Misuse | 1 | 2018 | 18 | 0.140 |
Why?
|
| Gene Editing | 1 | 2022 | 324 | 0.140 |
Why?
|
| Single-Blind Method | 5 | 2013 | 144 | 0.140 |
Why?
|
| Vaccination | 4 | 2022 | 371 | 0.140 |
Why?
|
| Linear Models | 2 | 2016 | 408 | 0.140 |
Why?
|
| Cardiovascular Diseases | 3 | 2019 | 848 | 0.140 |
Why?
|
| Telemetry | 1 | 2017 | 18 | 0.140 |
Why?
|
| Personhood | 1 | 2017 | 8 | 0.140 |
Why?
|
| Angiography, Digital Subtraction | 2 | 2015 | 138 | 0.140 |
Why?
|
| Receptors, KIR3DL1 | 1 | 2017 | 6 | 0.130 |
Why?
|
| Medication Adherence | 1 | 2019 | 205 | 0.130 |
Why?
|
| Bioprosthesis | 2 | 2015 | 42 | 0.130 |
Why?
|
| Angiography | 1 | 2018 | 151 | 0.130 |
Why?
|
| United Kingdom | 2 | 2016 | 81 | 0.130 |
Why?
|
| Frailty | 1 | 2019 | 125 | 0.130 |
Why?
|
| Psychological Theory | 2 | 2018 | 26 | 0.130 |
Why?
|
| Administrative Claims, Healthcare | 1 | 2017 | 11 | 0.130 |
Why?
|
| Actigraphy | 1 | 2017 | 49 | 0.130 |
Why?
|
| Signal Processing, Computer-Assisted | 1 | 2017 | 101 | 0.130 |
Why?
|
| Medicare Part B | 1 | 2017 | 11 | 0.130 |
Why?
|
| Hypercholesterolemia | 1 | 2017 | 70 | 0.130 |
Why?
|
| Ablation Techniques | 1 | 2017 | 26 | 0.130 |
Why?
|
| Molecular Sequence Data | 4 | 2011 | 1997 | 0.130 |
Why?
|
| Indocyanine Green | 1 | 2016 | 10 | 0.130 |
Why?
|
| Craniotomy | 1 | 2016 | 20 | 0.130 |
Why?
|
| T-Lymphocytes | 3 | 2011 | 1019 | 0.130 |
Why?
|
| Angina, Stable | 1 | 2016 | 11 | 0.130 |
Why?
|
| Patients | 1 | 2018 | 113 | 0.130 |
Why?
|
| Unnecessary Procedures | 1 | 2017 | 49 | 0.130 |
Why?
|
| Terminal Care | 1 | 2017 | 111 | 0.120 |
Why?
|
| Headache | 2 | 2021 | 58 | 0.120 |
Why?
|
| Injections | 1 | 2016 | 82 | 0.120 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2023 | 709 | 0.120 |
Why?
|
| Radiosurgery | 2 | 2017 | 69 | 0.120 |
Why?
|
| Anticonvulsants | 1 | 2017 | 103 | 0.120 |
Why?
|
| Killer Cells, Natural | 1 | 2017 | 219 | 0.120 |
Why?
|
| Sex Characteristics | 1 | 2017 | 202 | 0.120 |
Why?
|
| Hydrocephalus | 1 | 2016 | 43 | 0.120 |
Why?
|
| Computer Simulation | 3 | 2017 | 482 | 0.120 |
Why?
|
| Contraindications | 2 | 2015 | 52 | 0.120 |
Why?
|
| DNA, Viral | 1 | 2016 | 234 | 0.120 |
Why?
|
| Hospices | 1 | 2016 | 39 | 0.120 |
Why?
|
| Epilepsy | 1 | 2017 | 110 | 0.120 |
Why?
|
| Utilization Review | 1 | 2015 | 32 | 0.120 |
Why?
|
| Emergency Service, Hospital | 2 | 2016 | 1118 | 0.120 |
Why?
|
| Vasospasm, Intracranial | 1 | 2015 | 30 | 0.120 |
Why?
|
| Cerebral Infarction | 1 | 2016 | 84 | 0.110 |
Why?
|
| Gastrointestinal Tract | 1 | 2017 | 187 | 0.110 |
Why?
|
| Cerebral Ventriculitis | 1 | 2015 | 2 | 0.110 |
Why?
|
| Drug Therapy, Combination | 4 | 2019 | 467 | 0.110 |
Why?
|
| Psychology, Child | 1 | 2015 | 7 | 0.110 |
Why?
|
| Cardiology | 1 | 2017 | 170 | 0.110 |
Why?
|
| Antithrombins | 1 | 2015 | 16 | 0.110 |
Why?
|
| Psychology, Adolescent | 1 | 2015 | 27 | 0.110 |
Why?
|
| Fatal Outcome | 1 | 2015 | 125 | 0.110 |
Why?
|
| Brain Injuries, Traumatic | 1 | 2017 | 99 | 0.110 |
Why?
|
| AIDS Vaccines | 2 | 2014 | 72 | 0.110 |
Why?
|
| Congresses as Topic | 1 | 2015 | 79 | 0.110 |
Why?
|
| Brain Stem Neoplasms | 1 | 2014 | 3 | 0.110 |
Why?
|
| Adenoviridae | 2 | 2012 | 128 | 0.110 |
Why?
|
| Life Expectancy | 1 | 2014 | 33 | 0.110 |
Why?
|
| Cerebral Hemorrhage | 2 | 2012 | 100 | 0.110 |
Why?
|
| Societies, Medical | 1 | 2017 | 381 | 0.110 |
Why?
|
| Vaccines, Synthetic | 2 | 2011 | 78 | 0.110 |
Why?
|
| Decision Support Techniques | 1 | 2016 | 192 | 0.110 |
Why?
|
| Disease Models, Animal | 2 | 2020 | 2238 | 0.110 |
Why?
|
| Constriction, Pathologic | 1 | 2014 | 132 | 0.110 |
Why?
|
| Health Care Rationing | 1 | 2014 | 21 | 0.110 |
Why?
|
| Drainage | 1 | 2015 | 155 | 0.110 |
Why?
|
| Infant, Newborn | 2 | 2015 | 1375 | 0.110 |
Why?
|
| Caspases | 2 | 2006 | 176 | 0.110 |
Why?
|
| Lead | 1 | 2014 | 45 | 0.110 |
Why?
|
| Research Report | 1 | 2013 | 28 | 0.100 |
Why?
|
| Educational Measurement | 1 | 2015 | 219 | 0.100 |
Why?
|
| Infant | 2 | 2015 | 1664 | 0.100 |
Why?
|
| Observational Studies as Topic | 1 | 2013 | 63 | 0.100 |
Why?
|
| Verbal Behavior | 1 | 2013 | 36 | 0.100 |
Why?
|
| Diagnostic Self Evaluation | 1 | 2013 | 24 | 0.100 |
Why?
|
| Prevalence | 3 | 2014 | 1407 | 0.100 |
Why?
|
| Research Design | 2 | 2013 | 583 | 0.100 |
Why?
|
| Radiography | 2 | 2012 | 553 | 0.100 |
Why?
|
| Middle Cerebral Artery | 1 | 2013 | 50 | 0.100 |
Why?
|
| Immunization, Secondary | 2 | 2011 | 50 | 0.100 |
Why?
|
| Reference Values | 1 | 2013 | 333 | 0.100 |
Why?
|
| Cell Line | 2 | 2016 | 2055 | 0.100 |
Why?
|
| Hemangioma, Cavernous, Central Nervous System | 1 | 2012 | 8 | 0.100 |
Why?
|
| Heart Arrest | 1 | 2015 | 177 | 0.100 |
Why?
|
| Double-Blind Method | 1 | 2014 | 744 | 0.100 |
Why?
|
| Cerebrovascular Circulation | 2 | 2012 | 183 | 0.100 |
Why?
|
| Heparin | 2 | 2015 | 116 | 0.090 |
Why?
|
| Skull Base | 1 | 2012 | 14 | 0.090 |
Why?
|
| Consensus | 3 | 2018 | 185 | 0.090 |
Why?
|
| Emergency Medical Services | 3 | 2012 | 267 | 0.090 |
Why?
|
| Gene Products, pol | 1 | 2012 | 9 | 0.090 |
Why?
|
| Purinergic P2X Receptor Antagonists | 1 | 2012 | 7 | 0.090 |
Why?
|
| Government Regulation | 1 | 2012 | 41 | 0.090 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2015 | 1669 | 0.090 |
Why?
|
| Lymphoid Tissue | 2 | 2017 | 55 | 0.090 |
Why?
|
| Case-Control Studies | 2 | 2007 | 1131 | 0.090 |
Why?
|
| Piperazines | 1 | 2012 | 87 | 0.090 |
Why?
|
| Oligodendroglioma | 1 | 2011 | 7 | 0.090 |
Why?
|
| Perceptual Disorders | 1 | 2011 | 8 | 0.090 |
Why?
|
| Ventricular Function, Left | 1 | 2013 | 271 | 0.090 |
Why?
|
| Paclitaxel | 1 | 2012 | 103 | 0.090 |
Why?
|
| Models, Organizational | 1 | 2012 | 92 | 0.090 |
Why?
|
| Cells, Cultured | 1 | 2016 | 2177 | 0.090 |
Why?
|
| Frontal Lobe | 1 | 2011 | 64 | 0.090 |
Why?
|
| Renal Insufficiency | 2 | 2014 | 67 | 0.090 |
Why?
|
| Sensitivity and Specificity | 4 | 2021 | 1164 | 0.090 |
Why?
|
| HIV Seropositivity | 1 | 2011 | 84 | 0.090 |
Why?
|
| Educational Status | 1 | 2012 | 278 | 0.090 |
Why?
|
| Odds Ratio | 2 | 2012 | 759 | 0.090 |
Why?
|
| Aorta | 1 | 2011 | 110 | 0.090 |
Why?
|
| Magnetic Resonance Angiography | 1 | 2012 | 186 | 0.080 |
Why?
|
| Adaptation, Psychological | 1 | 2012 | 270 | 0.080 |
Why?
|
| Predictive Value of Tests | 3 | 2020 | 1105 | 0.080 |
Why?
|
| Limit of Detection | 1 | 2010 | 49 | 0.080 |
Why?
|
| Nursing Homes | 1 | 2016 | 672 | 0.080 |
Why?
|
| Muscle Tonus | 1 | 2010 | 3 | 0.080 |
Why?
|
| Valsalva Maneuver | 1 | 2010 | 11 | 0.080 |
Why?
|
| Respiratory Rate | 1 | 2010 | 15 | 0.080 |
Why?
|
| Intracranial Pressure | 1 | 2010 | 20 | 0.080 |
Why?
|
| Cell Separation | 1 | 2010 | 146 | 0.080 |
Why?
|
| Gene Products, env | 2 | 2009 | 18 | 0.080 |
Why?
|
| Absenteeism | 1 | 2010 | 39 | 0.080 |
Why?
|
| Hypertension | 1 | 2015 | 593 | 0.080 |
Why?
|
| Efficiency | 1 | 2010 | 41 | 0.080 |
Why?
|
| Insurance, Health | 1 | 2011 | 151 | 0.080 |
Why?
|
| Mass Screening | 1 | 2015 | 693 | 0.080 |
Why?
|
| Workers' Compensation | 1 | 2010 | 69 | 0.080 |
Why?
|
| Tachycardia, Atrioventricular Nodal Reentry | 1 | 2009 | 6 | 0.080 |
Why?
|
| Lymphocytes | 1 | 2010 | 203 | 0.080 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2011 | 224 | 0.080 |
Why?
|
| Benchmarking | 1 | 2010 | 134 | 0.080 |
Why?
|
| Immunologic Memory | 1 | 2011 | 290 | 0.080 |
Why?
|
| Genotype | 1 | 2011 | 668 | 0.080 |
Why?
|
| Hospitals | 1 | 2012 | 390 | 0.070 |
Why?
|
| Muscle Contraction | 1 | 2010 | 202 | 0.070 |
Why?
|
| Models, Econometric | 1 | 2008 | 14 | 0.070 |
Why?
|
| Recombination, Genetic | 1 | 2010 | 248 | 0.070 |
Why?
|
| Developed Countries | 1 | 2008 | 16 | 0.070 |
Why?
|
| Down-Regulation | 1 | 2010 | 319 | 0.070 |
Why?
|
| Platelet Glycoprotein GPIIb-IIIa Complex | 1 | 2008 | 24 | 0.070 |
Why?
|
| Anti-Bacterial Agents | 1 | 2015 | 800 | 0.070 |
Why?
|
| Cranial Fossa, Posterior | 1 | 2008 | 7 | 0.070 |
Why?
|
| Chromosomes, Human, Pair 14 | 1 | 2008 | 17 | 0.070 |
Why?
|
| Chromosomes, Human, Pair 11 | 1 | 2008 | 10 | 0.070 |
Why?
|
| Immunity, Mucosal | 2 | 2011 | 52 | 0.070 |
Why?
|
| Confidence Intervals | 1 | 2009 | 239 | 0.070 |
Why?
|
| Cost of Illness | 1 | 2010 | 169 | 0.070 |
Why?
|
| Vaccines, Attenuated | 1 | 2008 | 36 | 0.070 |
Why?
|
| Karyotyping | 1 | 2008 | 47 | 0.070 |
Why?
|
| Spinal Cord Compression | 1 | 2008 | 30 | 0.070 |
Why?
|
| Gliosis | 1 | 2008 | 28 | 0.070 |
Why?
|
| Phosphorylation | 3 | 2006 | 948 | 0.070 |
Why?
|
| Proprotein Convertase 9 | 2 | 2019 | 15 | 0.070 |
Why?
|
| Female Urogenital Diseases | 1 | 2008 | 5 | 0.070 |
Why?
|
| Occupational Health | 1 | 2010 | 187 | 0.070 |
Why?
|
| Host-Pathogen Interactions | 1 | 2010 | 266 | 0.070 |
Why?
|
| Ulcer | 1 | 2008 | 12 | 0.070 |
Why?
|
| DNA Primers | 1 | 2008 | 295 | 0.070 |
Why?
|
| Multicenter Studies as Topic | 2 | 2010 | 151 | 0.070 |
Why?
|
| Electric Stimulation | 1 | 2008 | 139 | 0.070 |
Why?
|
| Decompression, Surgical | 1 | 2008 | 70 | 0.070 |
Why?
|
| Mortality | 3 | 2016 | 161 | 0.070 |
Why?
|
| Blood Pressure | 1 | 2010 | 517 | 0.070 |
Why?
|
| Astrocytes | 1 | 2008 | 121 | 0.070 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2008 | 544 | 0.070 |
Why?
|
| Sequence Analysis, RNA | 1 | 2008 | 180 | 0.070 |
Why?
|
| Virus Internalization | 1 | 2008 | 90 | 0.070 |
Why?
|
| Cognition Disorders | 1 | 2008 | 218 | 0.060 |
Why?
|
| Drug Therapy | 1 | 2007 | 56 | 0.060 |
Why?
|
| Delivery of Health Care | 1 | 2011 | 437 | 0.060 |
Why?
|
| Feasibility Studies | 2 | 2020 | 577 | 0.060 |
Why?
|
| Tauopathies | 1 | 2006 | 19 | 0.060 |
Why?
|
| Postoperative Care | 3 | 2012 | 124 | 0.060 |
Why?
|
| Antigen Presentation | 1 | 2008 | 241 | 0.060 |
Why?
|
| Genetic Variation | 1 | 2008 | 387 | 0.060 |
Why?
|
| HIV-1 | 1 | 2011 | 723 | 0.060 |
Why?
|
| Health Care Surveys | 1 | 2007 | 289 | 0.060 |
Why?
|
| Cell Proliferation | 2 | 2022 | 1001 | 0.060 |
Why?
|
| Base Sequence | 1 | 2008 | 1332 | 0.060 |
Why?
|
| Protein Structure, Quaternary | 1 | 2006 | 100 | 0.060 |
Why?
|
| Costs and Cost Analysis | 1 | 2006 | 102 | 0.060 |
Why?
|
| Vaccinia virus | 2 | 2022 | 73 | 0.060 |
Why?
|
| Microscopy, Electron | 1 | 2005 | 251 | 0.060 |
Why?
|
| Sodium Dodecyl Sulfate | 1 | 2005 | 30 | 0.060 |
Why?
|
| Immune Tolerance | 1 | 2006 | 181 | 0.060 |
Why?
|
| Hypertrophy, Right Ventricular | 1 | 2004 | 7 | 0.060 |
Why?
|
| Scattering, Radiation | 1 | 2005 | 72 | 0.060 |
Why?
|
| Biopolymers | 1 | 2005 | 71 | 0.060 |
Why?
|
| Bundle-Branch Block | 1 | 2004 | 15 | 0.060 |
Why?
|
| Mice, Inbred BALB C | 1 | 2006 | 891 | 0.060 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 2005 | 183 | 0.060 |
Why?
|
| Life Style | 1 | 2006 | 317 | 0.050 |
Why?
|
| Cerebral Cortex | 1 | 2006 | 267 | 0.050 |
Why?
|
| Geriatric Assessment | 2 | 2017 | 160 | 0.050 |
Why?
|
| Cross-Linking Reagents | 1 | 2005 | 117 | 0.050 |
Why?
|
| Septal Occluder Device | 1 | 2024 | 12 | 0.050 |
Why?
|
| Ventricular Dysfunction, Right | 1 | 2004 | 50 | 0.050 |
Why?
|
| International Classification of Diseases | 1 | 2025 | 135 | 0.050 |
Why?
|
| Intestines | 1 | 2005 | 169 | 0.050 |
Why?
|
| Oxidation-Reduction | 1 | 2005 | 327 | 0.050 |
Why?
|
| Light | 1 | 2005 | 204 | 0.050 |
Why?
|
| Oxygen Consumption | 1 | 2004 | 212 | 0.050 |
Why?
|
| Recombinant Proteins | 3 | 2015 | 704 | 0.050 |
Why?
|
| Sodium-Glucose Transporter 2 | 1 | 2023 | 6 | 0.050 |
Why?
|
| Forecasting | 1 | 2004 | 233 | 0.050 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2006 | 219 | 0.050 |
Why?
|
| Vaccines, DNA | 3 | 2011 | 98 | 0.050 |
Why?
|
| Mental Health | 2 | 2017 | 372 | 0.050 |
Why?
|
| Anti-Retroviral Agents | 1 | 2023 | 76 | 0.050 |
Why?
|
| Diabetic Angiopathies | 1 | 2003 | 24 | 0.050 |
Why?
|
| Neurons | 2 | 2006 | 934 | 0.050 |
Why?
|
| Primates | 1 | 2022 | 55 | 0.050 |
Why?
|
| Probability | 1 | 2002 | 169 | 0.050 |
Why?
|
| Statistics, Nonparametric | 1 | 2002 | 215 | 0.050 |
Why?
|
| Nerve Tissue Proteins | 1 | 2004 | 429 | 0.050 |
Why?
|
| Receptors, CCR5 | 1 | 2022 | 59 | 0.040 |
Why?
|
| Nucleic Acid Amplification Techniques | 1 | 2021 | 29 | 0.040 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2021 | 34 | 0.040 |
Why?
|
| Walking | 2 | 2015 | 240 | 0.040 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2023 | 358 | 0.040 |
Why?
|
| Aortic Bodies | 1 | 2020 | 1 | 0.040 |
Why?
|
| Dabigatran | 1 | 2021 | 20 | 0.040 |
Why?
|
| Drug Carriers | 2 | 2015 | 181 | 0.040 |
Why?
|
| Facial Nerve | 1 | 2020 | 16 | 0.040 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2022 | 495 | 0.040 |
Why?
|
| Massachusetts | 1 | 2007 | 2096 | 0.040 |
Why?
|
| Whole-Body Irradiation | 1 | 2020 | 33 | 0.040 |
Why?
|
| Mutation | 2 | 2011 | 2629 | 0.040 |
Why?
|
| Preliminary Data | 1 | 2020 | 2 | 0.040 |
Why?
|
| Stem Cells | 1 | 2022 | 262 | 0.040 |
Why?
|
| Transplantation Conditioning | 1 | 2020 | 102 | 0.040 |
Why?
|
| Body Height | 1 | 2020 | 66 | 0.040 |
Why?
|
| Absorptiometry, Photon | 1 | 2020 | 76 | 0.040 |
Why?
|
| Posterior Cerebral Artery | 1 | 2020 | 13 | 0.040 |
Why?
|
| Area Under Curve | 1 | 2020 | 149 | 0.040 |
Why?
|
| Transplantation, Homologous | 1 | 2020 | 249 | 0.040 |
Why?
|
| Product Surveillance, Postmarketing | 1 | 2020 | 25 | 0.040 |
Why?
|
| Aspirin | 1 | 2021 | 172 | 0.040 |
Why?
|
| ROC Curve | 1 | 2020 | 288 | 0.040 |
Why?
|
| Medicaid | 1 | 2003 | 362 | 0.040 |
Why?
|
| Autografts | 1 | 2019 | 9 | 0.040 |
Why?
|
| Lymphocyte Activation | 2 | 2016 | 761 | 0.040 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2020 | 285 | 0.040 |
Why?
|
| Body Weight | 1 | 2020 | 379 | 0.040 |
Why?
|
| Antibodies, Viral | 2 | 2014 | 329 | 0.040 |
Why?
|
| Drug Administration Schedule | 1 | 2019 | 299 | 0.040 |
Why?
|
| Immunosuppressive Agents | 1 | 2020 | 381 | 0.040 |
Why?
|
| CRISPR-Cas Systems | 1 | 2022 | 364 | 0.040 |
Why?
|
| Models, Animal | 1 | 2019 | 240 | 0.040 |
Why?
|
| Tomography Scanners, X-Ray Computed | 1 | 2018 | 14 | 0.030 |
Why?
|
| Risk Adjustment | 2 | 2008 | 94 | 0.030 |
Why?
|
| Right to Die | 1 | 2017 | 3 | 0.030 |
Why?
|
| State Medicine | 1 | 2017 | 12 | 0.030 |
Why?
|
| Cell Degranulation | 1 | 2017 | 20 | 0.030 |
Why?
|
| Retreatment | 1 | 2017 | 45 | 0.030 |
Why?
|
| Patient Safety | 1 | 2020 | 243 | 0.030 |
Why?
|
| Prosthesis Implantation | 1 | 2017 | 32 | 0.030 |
Why?
|
| Headache Disorders | 1 | 2017 | 2 | 0.030 |
Why?
|
| Europe | 1 | 2017 | 197 | 0.030 |
Why?
|
| Telephone | 1 | 2017 | 122 | 0.030 |
Why?
|
| Prosthesis-Related Infections | 1 | 2017 | 35 | 0.030 |
Why?
|
| Medicare Part A | 1 | 2016 | 7 | 0.030 |
Why?
|
| Quality Indicators, Health Care | 1 | 2020 | 335 | 0.030 |
Why?
|
| Behavior, Animal | 1 | 2018 | 234 | 0.030 |
Why?
|
| Body Mass Index | 1 | 2020 | 874 | 0.030 |
Why?
|
| Immunophenotyping | 1 | 2016 | 197 | 0.030 |
Why?
|
| Mice | 2 | 2009 | 11003 | 0.030 |
Why?
|
| Antibody Specificity | 2 | 2008 | 102 | 0.030 |
Why?
|
| Intracranial Hemorrhages | 1 | 2017 | 68 | 0.030 |
Why?
|
| Schools | 1 | 2017 | 170 | 0.030 |
Why?
|
| Macrophages | 1 | 2022 | 1053 | 0.030 |
Why?
|
| Up-Regulation | 1 | 2017 | 375 | 0.030 |
Why?
|
| Health Services Research | 1 | 2017 | 271 | 0.030 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2018 | 288 | 0.030 |
Why?
|
| Aspartic Acid | 2 | 2006 | 34 | 0.030 |
Why?
|
| Polymerase Chain Reaction | 1 | 2016 | 518 | 0.030 |
Why?
|
| Blood Loss, Surgical | 1 | 2015 | 65 | 0.030 |
Why?
|
| Interviews as Topic | 1 | 2017 | 539 | 0.030 |
Why?
|
| Renal Dialysis | 1 | 2016 | 195 | 0.030 |
Why?
|
| Genetic Vectors | 2 | 2011 | 889 | 0.030 |
Why?
|
| Residence Characteristics | 1 | 2016 | 221 | 0.030 |
Why?
|
| Immunohistochemistry | 2 | 2008 | 901 | 0.030 |
Why?
|
| Social Behavior | 1 | 2015 | 89 | 0.030 |
Why?
|
| Arterial Occlusive Diseases | 1 | 2015 | 65 | 0.030 |
Why?
|
| Epitopes | 2 | 2006 | 292 | 0.030 |
Why?
|
| Blood Transfusion | 1 | 2015 | 162 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2017 | 1020 | 0.030 |
Why?
|
| Fluoroscopy | 1 | 2013 | 66 | 0.030 |
Why?
|
| Mitral Valve Stenosis | 1 | 2013 | 16 | 0.030 |
Why?
|
| Postoperative Period | 1 | 2013 | 137 | 0.030 |
Why?
|
| Cross Infection | 1 | 2015 | 167 | 0.030 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2014 | 143 | 0.020 |
Why?
|
| Cytokines | 1 | 2017 | 944 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2014 | 375 | 0.020 |
Why?
|
| Dementia | 1 | 2016 | 263 | 0.020 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2014 | 153 | 0.020 |
Why?
|
| Cross-Sectional Studies | 2 | 2012 | 2621 | 0.020 |
Why?
|
| Bias | 1 | 2013 | 114 | 0.020 |
Why?
|
| Equipment Safety | 1 | 2013 | 24 | 0.020 |
Why?
|
| Electrodes, Implanted | 1 | 2013 | 38 | 0.020 |
Why?
|
| Statistics as Topic | 1 | 2013 | 147 | 0.020 |
Why?
|
| Health Services for the Aged | 1 | 2013 | 49 | 0.020 |
Why?
|
| Reference Standards | 1 | 2012 | 74 | 0.020 |
Why?
|
| Otitis | 1 | 2012 | 3 | 0.020 |
Why?
|
| Lung Diseases | 1 | 2014 | 183 | 0.020 |
Why?
|
| Pacific States | 1 | 2012 | 1 | 0.020 |
Why?
|
| Everolimus | 1 | 2012 | 22 | 0.020 |
Why?
|
| Prasugrel Hydrochloride | 1 | 2012 | 12 | 0.020 |
Why?
|
| Osteomyelitis | 1 | 2012 | 24 | 0.020 |
Why?
|
| Global Health | 1 | 2013 | 183 | 0.020 |
Why?
|
| Medical Audit | 1 | 2012 | 65 | 0.020 |
Why?
|
| Temporal Bone | 1 | 2012 | 39 | 0.020 |
Why?
|
| Research | 1 | 2013 | 196 | 0.020 |
Why?
|
| Risk Management | 1 | 2012 | 39 | 0.020 |
Why?
|
| Regional Blood Flow | 1 | 2012 | 110 | 0.020 |
Why?
|
| Infusions, Intravenous | 1 | 2012 | 176 | 0.020 |
Why?
|
| Blood Vessel Prosthesis | 1 | 2013 | 212 | 0.020 |
Why?
|
| Popliteal Artery | 1 | 2011 | 24 | 0.020 |
Why?
|
| Hemodynamics | 1 | 2013 | 249 | 0.020 |
Why?
|
| Neuroprotective Agents | 1 | 2012 | 77 | 0.020 |
Why?
|
| Diabetes Mellitus | 1 | 2016 | 541 | 0.020 |
Why?
|
| New England | 1 | 2012 | 269 | 0.020 |
Why?
|
| Sequence Analysis, Protein | 1 | 2011 | 34 | 0.020 |
Why?
|
| Quebec | 1 | 2011 | 14 | 0.020 |
Why?
|
| Clone Cells | 1 | 2011 | 116 | 0.020 |
Why?
|
| Cluster Analysis | 1 | 2012 | 263 | 0.020 |
Why?
|
| Tissue Plasminogen Activator | 1 | 2012 | 127 | 0.020 |
Why?
|
| Evolution, Molecular | 2 | 2004 | 324 | 0.020 |
Why?
|
| Adenoviruses, Human | 1 | 2011 | 10 | 0.020 |
Why?
|
| Functional Laterality | 1 | 2011 | 138 | 0.020 |
Why?
|
| Fibrinolytic Agents | 1 | 2012 | 173 | 0.020 |
Why?
|
| Biopsy | 1 | 2012 | 449 | 0.020 |
Why?
|
| Bayes Theorem | 1 | 2011 | 123 | 0.020 |
Why?
|
| Hospitals, Teaching | 1 | 2011 | 106 | 0.020 |
Why?
|
| Socioeconomic Factors | 1 | 2013 | 788 | 0.020 |
Why?
|
| Kidney Failure, Chronic | 1 | 2012 | 205 | 0.020 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 1 | 2011 | 119 | 0.020 |
Why?
|
| Attention | 1 | 2011 | 148 | 0.020 |
Why?
|
| Inflammation | 1 | 2016 | 1162 | 0.020 |
Why?
|
| Apoptosis | 2 | 2006 | 1094 | 0.020 |
Why?
|
| Virulence | 1 | 2010 | 195 | 0.020 |
Why?
|
| Ganglia, Parasympathetic | 1 | 2009 | 2 | 0.020 |
Why?
|
| Disease-Free Survival | 1 | 2010 | 249 | 0.020 |
Why?
|
| Treatment Failure | 1 | 2010 | 201 | 0.020 |
Why?
|
| Intestinal Mucosa | 1 | 2011 | 243 | 0.020 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2011 | 247 | 0.020 |
Why?
|
| Vagus Nerve | 1 | 2009 | 21 | 0.020 |
Why?
|
| Autonomic Nervous System | 1 | 2009 | 36 | 0.020 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2011 | 313 | 0.020 |
Why?
|
| Heparin, Low-Molecular-Weight | 1 | 2008 | 26 | 0.020 |
Why?
|
| Epithelium | 1 | 2009 | 96 | 0.020 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2012 | 677 | 0.020 |
Why?
|
| Cervix Uteri | 1 | 2009 | 61 | 0.020 |
Why?
|
| Sequence Alignment | 1 | 2009 | 302 | 0.020 |
Why?
|
| Resource Allocation | 1 | 2008 | 19 | 0.020 |
Why?
|
| Glial Fibrillary Acidic Protein | 1 | 2008 | 41 | 0.020 |
Why?
|
| Plaque, Amyloid | 1 | 2008 | 41 | 0.020 |
Why?
|
| Rabbits | 1 | 2009 | 333 | 0.020 |
Why?
|
| Staining and Labeling | 1 | 2009 | 126 | 0.020 |
Why?
|
| Guideline Adherence | 1 | 2010 | 306 | 0.020 |
Why?
|
| Robotics | 1 | 2009 | 87 | 0.020 |
Why?
|
| Phylogeny | 1 | 2009 | 385 | 0.020 |
Why?
|
| Antigen-Presenting Cells | 1 | 2008 | 178 | 0.020 |
Why?
|
| Spleen | 1 | 2009 | 483 | 0.020 |
Why?
|
| Patient Selection | 1 | 2009 | 487 | 0.020 |
Why?
|
| Kinetics | 1 | 2008 | 766 | 0.020 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2006 | 93 | 0.020 |
Why?
|
| Indoleamine-Pyrrole 2,3,-Dioxygenase | 1 | 2006 | 7 | 0.020 |
Why?
|
| Lymphocyte Subsets | 1 | 2006 | 37 | 0.020 |
Why?
|
| CD3 Complex | 1 | 2006 | 65 | 0.010 |
Why?
|
| Receptors, Interleukin-2 | 1 | 2006 | 71 | 0.010 |
Why?
|
| Serine | 1 | 2006 | 91 | 0.010 |
Why?
|
| Transforming Growth Factor beta1 | 1 | 2006 | 60 | 0.010 |
Why?
|
| Nerve Degeneration | 1 | 2006 | 72 | 0.010 |
Why?
|
| Heart Block | 1 | 2005 | 22 | 0.010 |
Why?
|
| Caspase 3 | 1 | 2006 | 108 | 0.010 |
Why?
|
| Peptide Hydrolases | 1 | 2006 | 80 | 0.010 |
Why?
|
| Cytomegalovirus Infections | 1 | 2006 | 68 | 0.010 |
Why?
|
| Antibodies | 1 | 2006 | 186 | 0.010 |
Why?
|
| CD4 Antigens | 1 | 2006 | 151 | 0.010 |
Why?
|
| Postmortem Changes | 1 | 2004 | 12 | 0.010 |
Why?
|
| Transforming Growth Factor beta | 1 | 2006 | 174 | 0.010 |
Why?
|
| Interleukin-10 | 1 | 2006 | 161 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-fyn | 1 | 2004 | 6 | 0.010 |
Why?
|
| Viral Regulatory and Accessory Proteins | 1 | 2004 | 21 | 0.010 |
Why?
|
| Temporal Lobe | 1 | 2004 | 46 | 0.010 |
Why?
|
| Caspase 6 | 1 | 2004 | 17 | 0.010 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2004 | 234 | 0.010 |
Why?
|
| src-Family Kinases | 1 | 2004 | 64 | 0.010 |
Why?
|
| Antigens | 1 | 2004 | 149 | 0.010 |
Why?
|
| Antigens, Viral | 1 | 2004 | 137 | 0.010 |
Why?
|
| Amino Acid Substitution | 1 | 2004 | 239 | 0.010 |
Why?
|
| In Vitro Techniques | 1 | 2004 | 490 | 0.010 |
Why?
|
| Binding Sites | 1 | 2006 | 914 | 0.010 |
Why?
|
| Blotting, Western | 1 | 2004 | 614 | 0.010 |
Why?
|
| Gene Deletion | 1 | 2004 | 312 | 0.010 |
Why?
|
| Microscopy, Fluorescence | 1 | 2004 | 402 | 0.010 |
Why?
|
| Epitope Mapping | 1 | 2002 | 52 | 0.010 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2004 | 329 | 0.010 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2006 | 645 | 0.010 |
Why?
|
| Acute Disease | 1 | 2003 | 672 | 0.010 |
Why?
|
| Aging | 1 | 2006 | 754 | 0.010 |
Why?
|
| Models, Biological | 1 | 2004 | 1187 | 0.010 |
Why?
|